Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29118739 | 1.00 | KDM4E (0.44) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL27837711 | 1.00 | KDM4E (0.44) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL4611332 | 0.96 | KDM4E (0.44) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL290355 | 0.96 | KDM4E (0.44) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL2745700 | 0.96 | KDM4E (0.44) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL1162330 | 0.96 | KDM4E (0.44) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL3335410 | 0.96 | KDM4E (0.44) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL525690 | 0.96 | KDM4E (0.44) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL2223196 | 0.96 | KDM4E (0.44) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL2299446 | 0.95 | KDM4E (0.41) | KDM4EDUSP3MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116242-B1 | NEW PHARMACEUTICAL COMPOSITION | SHENZHEN SALUBRIS PHARM CO LTD (CN) | 2016-10-12 | — | — | EP | claimed |
| US-RE46496-E1 | Metformin glycinate for blood glucose control | LABORATORIOS SILANES S.A. DE C.V. (MX) | 2017-08-01 | — | — | US | disclosed |
| US-8703183-B2 | Metformin glycinate salt for blood glucose control | LABORATORIOS SILANES S.A. DE C.V. (MX) | 2014-04-22 | — | — | US | disclosed |
| US-20110171142-A1 | Metformin glycinate salt for blood glucose control | Silanes | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171142-A1 | Metformin glycinate salt for blood glucose control | SLC5A1, SLC5A2, SLC2A1 | KDM4E 1922/4885DUSP3 1738/4885MEN1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.